Baird lowered the firm’s price target on Sage Therapeutics to $9 from $13 and keeps a Neutral rating on the shares. The firm noted Sage announced the failure the phase 2 LIGHTWAVE trial of dalzanemdor in Alzheimer’s disease, which we believe puts essentially all investor focus on Zurzuvae for going forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage study failure removes another potential upside driver, says Stifel
- Sage Therapeutics falls 21% after Phase 2 dalzanemdor results miss endpoint
- Sage Therapeutics’ dalzanemdor did not meet primary endpoint in Phase 2 study
- Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
- CVS Health upgraded, Mobileye downgraded: Wall Street’s top analyst calls